secwatch.observer — SEC 8-K summary
======================================

Issuer:     Chemomab Therapeutics Ltd. (CMMB)
CIK:        0001534248
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001178913-23-000010
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Chemomab CM-101 Phase 2a NASH trial meets safety endpoint; shows positive fibrosis biomarker activity
--------------------------------------------------------------------------------

- Trial met primary endpoint: safety and tolerability; no significant injection site reactions, no anti-drug antibodies.
- 23 NASH patients (F1c-F3) received 8 SC doses of 5 mg/kg or placebo over 16 weeks.
- CM-101 showed greater improvements vs placebo in fibrosis biomarkers ProC-3, ProC-4, ProC-18, TIMP-1, ELF.
- Nearly 60% of CM-101 patients responded in ≥3 fibrosis biomarkers at week 20 vs 0% placebo.
- Higher baseline CCL24 correlated with greater biomarker reductions; FibroScan liver stiffness improved vs placebo.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/0001178913-23-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534248/000117891323000010/zk2328943.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer